Stock Fundamentals

Company Information

Company Name
HUTCHMED DRC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US44842L1035
CIK: 0001648257
CUSIP: 44842L103
Currency: USD
Full Time Employees: 1,796
Phone: 852 2121 8200
Fiscal Year End: December
IPO Date: Mar 17, 2016
Description:

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Address:

Cheung Kong Center, Hong Kong, Hong Kong

Directors & Officers

Name Title Year Born
Mr. Chig Fung Cheng BEc, CA Acting CEO, CFO & Executive Director 1967
Dr. Wei-Guo Su B.Sc., Ph.D. CEO, Chief Scientific Officer & Executive Director (Leave of Absence) 1959
Ms. Yiling Cui Executive VP & Head of Operations NA
Dr. Xinhui Hu Ph.D. Executive Vice President & Chief Technical Officer 1973
Mr. David Ng Head of Investor Relations & Capital Strategies NA
Mr. Charles George Rupert Nixon Group General Counsel 1970
Mr. Kin Hung Lee M.B.A. Senior Vice President of Corporate Management & Communications 1977
Ms. Selina Zhang Senior Vice President of Global Human Resources NA
Dr. Qingmei Wang Ph.D. Executive Vice President of Business Development & Strategic Alliances 1963
Dr. Thomas Fu Senior Vice President of Global Quality NA

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Schroder Investment Management Group 1.48M Mar 31, 2026 0.86% $0.02 -35.18%
Allianz Asset Management AG 837.48K Mar 31, 2026 0.49% $0.01 -7.85%
State Street Corp 304.83K Mar 31, 2026 0.18% $0.00 -5.13%
AIA Group Ltd 291.23K Mar 31, 2026 0.17% $0.06 -7.68%
M&G PLC 255.47K Mar 31, 2026 0.15% $0.02 -1.38%
Amundi 232.25K Mar 31, 2026 0.14% $0.00 3.99%
Renaissance Technologies Corp 132.06K Mar 31, 2026 0.08% $0.00 -2.10%
BNP Paribas Arbitrage, SA 106.50K Mar 31, 2026 0.06% $0.00 239.21%
Crossmark Global Holdings, Inc. 84.96K Mar 31, 2026 0.05% $0.02 61.91%
Jane Street Group LLC 76.51K Mar 31, 2026 0.04% $0.00 -29.15%
Tidal Investments LLC. 67.39K Mar 31, 2026 0.04% $0.00 0.00%
Dimensional Fund Advisors, Inc. 55.97K Mar 31, 2026 0.03% $0.00 0.00%
XY Capital Ltd 48.39K Mar 31, 2026 0.03% $0.72 -16.00%
UBS Group AG 44.76K Mar 31, 2026 0.03% $0.00 -26.34%
Citadel Advisors Llc 30.51K Mar 31, 2026 0.02% $0.00 18.42%
Millennium Management LLC 28.01K Mar 31, 2026 0.02% $0.00 -25.60%
Janney Montgomery Scott LLC 24.42K Mar 31, 2026 0.01% $0.00 0.00%
Geode Capital Management, LLC 21.83K Mar 31, 2026 0.01% $0.00 0.00%
Janney Capital Management LLC 21.18K Dec 31, 2025 0.01% $0.02 64.91%
JustInvest LLC 20.43K Mar 31, 2026 0.01% $0.00 20.96%

Shares Statistics

Shares Outstanding: 171.95M
Shares Float: 508.44M
% Insiders: 0.90%
% Institutions: 257.40%
Short % Float: 0.21%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Schroder Asian Growth SGD A Dis 770.34K 0.45% ▲ 0.00% Feb 28, 2026
2 Allianz Oriental Income P USD 598.50K 0.35% ▼ 2.36% Apr 30, 2026
3 Janney Global Small Cap 339.34K 0.20% ▲ 1,342.83% Mar 31, 2026
4 M&G Global Emerging Markets GBP I Acc 198.92K 0.12% ▼ 1.26% Feb 28, 2026
5 State St Gb Sm Cp Eq ex-US Idx NL Cl A 120.45K 0.07% ▲ 0.00% Apr 30, 2026
6 BSO Bio Santé C 100.00K 0.06% ▲ 0.00% Apr 30, 2026
7 Steward Values Enhanced International I 84.10K 0.05% ▲ 0.00% Apr 30, 2026
8 State St Gb All Cp Eq ex-US Idx SL Cl I 74.75K 0.04% ▲ 0.00% Nov 30, 2025
9 State Street® SPDR® Ptf Dev Wld exUS ETF 70.14K 0.04% ▲ 0.00% Apr 30, 2026
10 Tema Oncology ETF 68.70K 0.04% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $812.09M
Trailing P/E: 4.24
Forward P/E: 43.67

Financial Highlights

Market Cap: $1.93B
EBITDA: $-25.85M
P/E Ratio: $4.24
PEG Ratio: $0.00
Book Value: $7.20
Earnings/Share: $2.65
Profit Margin: 83.30%
Operating Margin: -13.16%
ROA (TTM): -1.62%
ROE (TTM): 45.25%
Revenue (TTM): $548.51M
Revenue/Share (TTM): $3.20
Earnings Growth (YOY): -98.10%
Revenue Growth (YOY): -16.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.96x 0.08x 0.29x -19.05x -2.32x
2024-12-31 2.83x 0.11x 0.39x -15.22x -2.73x
2023-12-31 2.72x 0.11x 0.42x 24.21x 3.13x
2022-12-31 2.37x 0.04x 0.38x -628.48x -0.06x
2021-12-31 3.89x 0.03x 0.24x -554.59x -0.15x
2020-12-31 3.35x 0.07x 0.28x -252.37x -0.17x
2019-12-31 2.80x 0.11x 0.33x -148.33x -0.22x
2018-12-31 4.33x 0.07x 0.23x -91.81x -0.33x
2017-12-31 4.13x 0.07x 0.19x -36.71x -0.65x
2016-12-31 1.76x 0.27x 0.40x -28.63x -1.13x
2015-12-31 1.11x 0.65x 0.55x -6.96x -6.98x
2014-12-31 1.19x 1.66x 0.54x -12.03x -3.82x
2013-12-31 0.85x 0.66x 0.44x -0.70x 4.89x
2012-12-31 1.25x 0.15x 0.49x -15.05x 0.77x
2011-12-31 1.59x 0.46x 0.60x 7.34x 2.65x
2010-12-31 1.59x 0.41x 0.57x -5.49x 10.33x
2009-12-31 1.68x 0.12x 0.41x -11.55x -173.00x
2008-12-31 2.34x 0.10x 0.28x -26.95x -0.79x
2007-12-31 2.95x 0.07x 0.23x -32.50x -1.11x
2006-12-31 4.28x 0.07x 0.17x -13.85x -2.83x
2005-12-31 0.33x -0.22x 1.45x -11.56x -2.16x
2004-12-31 N/A N/A N/A -17.51x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about HCM.US!